{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:57:11Z","timestamp":1771660631690,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1016\/j.vaccine.2009.01.038","type":"journal-article","created":{"date-parts":[[2009,2,4]],"date-time":"2009-02-04T17:03:11Z","timestamp":1233766991000},"page":"1691-1699","source":"Crossref","is-referenced-by-count":28,"title":["Effective post-exposure protection against lethal orthopoxviruses infection by vaccinia immune globulin involves induction of adaptive immune response"],"prefix":"10.1016","volume":"27","author":[{"given":"Shlomo","family":"Lustig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galia","family":"Maik-Rachline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nir","family":"Paran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Melamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomer","family":"Israely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noam","family":"Erez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadav","family":"Orr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaul","family":"Reuveny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arie","family":"Ordentlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orgad","family":"Laub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avigdor","family":"Shafferman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baruch","family":"Velan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2009.01.038_bib1","series-title":"The global eradication of smallpox: final report of the global commission for the certification of smallpox eradication, December 1979","author":"World Health Organization","year":"1980"},{"issue":"February (4)","key":"10.1016\/j.vaccine.2009.01.038_bib2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/rmv.571","article-title":"New generation smallpox vaccines: a review of preclinical and clinical data","volume":"18","author":"Artenstein","year":"2008","journal-title":"Rev Med Virol"},{"issue":"March (11\u201312)","key":"10.1016\/j.vaccine.2009.01.038_bib3","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1016\/j.vaccine.2003.10.022","article-title":"Mouse neurotoxicity test for vaccinia-based smallpox vaccines","volume":"22","author":"Li","year":"2004","journal-title":"Vaccine"},{"issue":"July (2)","key":"10.1016\/j.vaccine.2009.01.038_bib4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1086\/375825","article-title":"Smallpox vaccination: a review. Part II. Adverse events","volume":"37","author":"Fulginiti","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"May (3)","key":"10.1016\/j.vaccine.2009.01.038_bib5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ijid.2005.12.001","article-title":"Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy","volume":"10","author":"Wittek","year":"2006","journal-title":"Int J Infect Dis"},{"issue":"February (7077)","key":"10.1016\/j.vaccine.2009.01.038_bib6","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nature04295","article-title":"Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection","volume":"439","author":"Stittelaar","year":"2006","journal-title":"Nature"},{"issue":"October (Pt 10)","key":"10.1016\/j.vaccine.2009.01.038_bib7","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1099\/vir.0.82068-0","article-title":"Short-term, but not post-exposure, protection against lethal orthopoxvirus challenge after immunization with modified vaccinia virus Ankara","volume":"87","author":"Staib","year":"2006","journal-title":"J Gen Virol"},{"issue":"January (1\u20132)","key":"10.1016\/j.vaccine.2009.01.038_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0166-3542(02)00199-7","article-title":"A review of compounds exhibiting anti-orthopoxvirus activity in animal models","volume":"57","author":"Smee","year":"2003","journal-title":"Antiviral Res"},{"issue":"January (1\u20132)","key":"10.1016\/j.vaccine.2009.01.038_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0166-3542(02)00196-1","article-title":"Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections","volume":"57","author":"Baker","year":"2003","journal-title":"Antiviral Res"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2009.01.038_bib10","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0165-6147(02)02091-6","article-title":"Cidofovir in the therapy and short-term prophylaxis of poxvirus infections","volume":"23","author":"De Clercq","year":"2002","journal-title":"Trends Pharmacol Sci"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2009.01.038_bib11","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1128\/AAC.47.10.3275-3280.2003","article-title":"Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice","volume":"47","author":"Quenelle","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"October (20)","key":"10.1016\/j.vaccine.2009.01.038_bib12","doi-asserted-by":"crossref","first-page":"13139","DOI":"10.1128\/JVI.79.20.13139-13149.2005","article-title":"An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge","volume":"79","author":"Yang","year":"2005","journal-title":"J Virol"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2009.01.038_bib13","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/AAC.00879-06","article-title":"Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice","volume":"51","author":"Quenelle","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"April (28)","key":"10.1016\/j.vaccine.2009.01.038_bib14","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0140-6736(62)91935-9","article-title":"Antivaccinial gamma-globulin in the control of smallpox","volume":"1","author":"Hobday","year":"1962","journal-title":"Lancet"},{"issue":"April (2)","key":"10.1016\/j.vaccine.2009.01.038_bib15","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1586\/14787210.4.2.277","article-title":"Smallpox antiviral drug development: satisfying the animal efficacy rule","volume":"4","author":"Jordan","year":"2006","journal-title":"Exp Rev Anti-infective Ther"},{"issue":"3","key":"10.1016\/j.vaccine.2009.01.038_bib16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/095632020801900302","article-title":"Progress in the discovery of compounds inhibiting Orthopoxviruses in animal models","volume":"19","author":"Smee","year":"2008","journal-title":"Antivir Chem Chemother"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2009.01.038_bib17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.0042-9007.2004.00397.x","article-title":"Intravenous immunoglobulin products contain neutralizing antibodies to vaccinia","volume":"86","author":"Goldsmith","year":"2004","journal-title":"Vox Sanguinis"},{"issue":"April (Pt 4)","key":"10.1016\/j.vaccine.2009.01.038_bib18","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1099\/vir.0.80660-0","article-title":"An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model","volume":"86","author":"Law","year":"2005","journal-title":"J Gen Virol"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2009.01.038_bib19","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1128\/AAC.49.7.2634-2641.2005","article-title":"Biological activity of an intravenous preparation of human vaccinia immune globulin in mouse models of vaccinia virus infection","volume":"49","author":"Shearer","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2009.01.038_bib20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1128\/MMBR.55.1.80-122.1991","article-title":"Poxvirus pathogenesis","volume":"55","author":"Buller","year":"1991","journal-title":"Microbiol Rev"},{"issue":"October (Pt 10)","key":"10.1016\/j.vaccine.2009.01.038_bib21","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1099\/vir.0.81090-0","article-title":"Ectromelia virus: the causative agent of mousepox","volume":"86","author":"Esteban","year":"2005","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2009.01.038_bib22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4049\/jimmunol.63.4.341","article-title":"Mouse-pox (infectious ectromelia of mice): a review","volume":"63","author":"Fenner","year":"1949","journal-title":"J Immunol"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2009.01.038_bib23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/sj.icb.7100118","article-title":"Correlates of protective immunity in poxvirus infection: where does antibody stand?","volume":"86","author":"Panchanathan","year":"2008","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2009.01.038_bib24","doi-asserted-by":"crossref","unstructured":"Paran N, Suezer Y, Lustig S, Israely T, Schwantes A, Melamed S, et al. Post-exposure immunization with vaccinia virus MVA or conventional Lister vaccine provides solid protection in murine model for human smallpox. J Infect Dis 2009;199(January (1)):39\u201348.","DOI":"10.1086\/595565"},{"key":"10.1016\/j.vaccine.2009.01.038_bib25","series-title":"Strains of human viruses","author":"Majer","year":"1972"},{"key":"10.1016\/j.vaccine.2009.01.038_bib26","first-page":"36","article-title":"Preparation of vaccine against smallpox in chorioalantois membranes of chicken embryos","volume":"9","author":"Gerichter","year":"1966","journal-title":"Public Health (Israeli Ministry of Health, Jerusalem)"},{"issue":"December (1\u20132)","key":"10.1016\/j.vaccine.2009.01.038_bib27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jviromet.2005.05.027","article-title":"Development of a tissue-culture-based enzyme-immunoassay method for the quantitation of anti-vaccinia-neutralizing antibodies in human sera","volume":"130","author":"Eyal","year":"2005","journal-title":"J Virol Methods"},{"issue":"November (45)","key":"10.1016\/j.vaccine.2009.01.038_bib28","first-page":"7743","article-title":"Tail scarification with Vaccinia virus Lister as a model for evaluation of smallpox vaccine potency in mice","volume":"25","author":"Melamed","year":"2007","journal-title":"Vaccine"},{"issue":"September (6)","key":"10.1016\/j.vaccine.2009.01.038_bib29","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1086\/422998","article-title":"Safety and pharmacokinetic evaluation of intravenous vaccinia immune globulin in healthy volunteers","volume":"39","author":"Hopkins","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"October (7)","key":"10.1016\/j.vaccine.2009.01.038_bib30","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1086\/423851","article-title":"Clinical and immune responses after revaccination of israeli adults with the Lister strain of vaccinia virus","volume":"190","author":"Orr","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2009.01.038_bib31","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0140-6736(48)91599-2","article-title":"The pathogenesis of the acute exanthems; an interpretation based on experimental investigations with mousepox; infectious ectromelia of mice","volume":"2","author":"Fenner","year":"1948","journal-title":"Lancet"},{"issue":"January (2)","key":"10.1016\/j.vaccine.2009.01.038_bib32","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.virol.2003.11.015","article-title":"Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model","volume":"318","author":"Buller","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2009.01.038_bib33","series-title":"Medical management of smallpox (Vaccinia) vaccine adverse reactions: Vaccinia immune globulin and cidofovir","author":"Centers for Disease Control and Prevention","year":"2003"},{"issue":"November (21)","key":"10.1016\/j.vaccine.2009.01.038_bib34","doi-asserted-by":"crossref","first-page":"13454","DOI":"10.1128\/JVI.79.21.13454-13462.2005","article-title":"Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge","volume":"79","author":"Lustig","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2009.01.038_bib35","unstructured":"Centers for Disease Control Prevention. Vaccinia (smallpox) vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2001;50(RR-10):1\u201325."},{"key":"10.1016\/j.vaccine.2009.01.038_bib36","unstructured":"Centers for Disease Control Prevention. Smallpox vaccination and adverse reactions: guidance for clinicians. MMWR Morb Mortal Wkly Rep 2003;52(RR-4):1\u201328."},{"issue":"August (2)","key":"10.1016\/j.vaccine.2009.01.038_bib37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1542\/peds.18.2.177","article-title":"Hyperimmune vaccinal gamma globulin; source, evaluation, and use in prophylaxis and therapy","volume":"18","author":"Kempe","year":"1956","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2009.01.038_bib38","unstructured":"Stopera S, Genereux M, Edge M, inventors; U.S. 2006\/0110407 A1, assignee. Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection. U.S. 2006."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09001388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09001388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T21:36:41Z","timestamp":1684877801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X09001388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S0264410X09001388"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.01.038","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}